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Retinal Venous Occlusive Disease
Vernon K.W. Wong MD*
Occlusions of the retinal venous system are the second most
common retinal vascular disease after diabetic retinopathy. Patients
present with sudden vision loss or may be asymptomatic. Retinal
vein occlusions are classified into branch or central occlusions.
Laser photocoagulation and vitreoretinal surgical techniques are
used to treat the complications ofmacularedema, neovascularization,
vitreous hemorrhage and retinal detachment.
Retinal Venous Occlusive Disease
Occlusions of the retinal venous system are the second most
common retinal vascular disease after diabetic retinopathy.’2Reti
nal venous occlusions are classified into branch retinal vein occlu
sions (BRVO) and central retinal vein occlusions (CRVO).
Branch Retinal Vein Occlusion (BRVO)
Clinical Presentation
Branch retinal vein occlusions usually occur in people in their 60s,
affecting men and women equally.3Patients may notice an acute,
painless loss of vision if there is macular edema, ischemic
maculopathy, or intraretinal hemorrhage involving the fovea. A
BRVO occurring in a nasal retinal quadrant can be asymptomatic.
A longstanding BRVO may present with floaters or an abrupt
decrease in vision from vitreous hemorrhage or retinal detachment.
In a recent BRVO, ophthalmoscopy can reveal intraretinal hem
orrhages in a segmental pattern, cotton-wool spots, and macular
edema. In a chronic BRVO, collateral vessels, macular retinal
pigment epithelium changes, and neovascularization of the retina or
disc may develop. (Fig 1)
Branch retinal vein occlusions occur most commonly in the
superotemporal retinal quadrant, and about 10% of patients with
BRVO will develop retinal vein occlusion in the fellow eye.4’
Systemic hypertension is a risk factor for a BRVO.35
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Classification
Branch retinal vein occlusions are categorized into ischemic and
nonischemic types. A non ischemic BRVO is defined as less than 5
disc diameters of retinal capillary nonperfusion as documented by
fluorescein angiography, while an ischemic BRVO is defined as
greater than 5 disc diameters.3’4
Complications
About 50% of patients with BRVOs have a final visual acuity of
20/40 or greater.4’Patients with nonischemic BRVOs may lose
vision secondary to macular edema. Patients with ischemic BRVOs
can lose vision from macular edema, ischemic maculopathy, vitre
ous hemorrhage, or retinal detachment. If ischemia occurs in the
macula, the patient may notice central vision loss, while ophthal
moscopy may not reveal macular edema. A fluorescein angiogram
will demonstrate an enlarged and irregular foveal avascular zone.
(Fig 2)
Approximately 30-40% of patients with ischemic BRVOs de
velop neovascularization of the retina or disc.23’6In approximately
60% of the patients who develop neovascularization, traction from
the vitreous causes these new vessels to bleed leading to vitreous
hemorrhage.2’6Rarely, traction on the new vessels may lead to a
traction retinal detachment or a retinal tear that progresses to a
rhegmatogenous retinal detachment.2-6
Treatment
Patients with a nonischemic BRVO without macular edema are
followed clinically for the development of macular edema and for
progression into an ischemic BRVO and its complications. The
Branch Vein Occlusion Study was a multicenter, randomized,
controlled clinical trial designed to answer if argon laser photoco
agulation could improve visual acuity in eyes with BRVO and
macular ecema reducing vision to 20/40 or worse.7 The study found
that 65% of eyes treated with argon laser photocoagulation com
pared to 37% of control gained 2 or more lines of vision, a difference
that was statistically significant. The study investigators recom
mend argon laserphotocoagulation forpatients with BRVOs at least
3 months old and vision loss 20/40 or worse from macular edema.7
The Branch Vein Occlusion Study was also designed to see if
peripheral scatter argon laser photocoagulation could prevent reti
nal neovascularization and vitreous hemorrhage.6It was found that
neovascularization and vitreous hemorrhage in eyes with preexist
ing neovascularization were significantly less in treated eyes. Data
from the study suggested that there was minimal risk for severe
vision loss even if laser was performed after the development of
neovascularization. The study recommended scatter argon laser
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Fig. 1.—Left eye. Fundus photograph of an ischemic, superotemporal
BRVO demonstrates elevated neovascularization of the disc and retina,
and preretinal hemorrhage inferior to the disc.
Fig. 3.—Left eye. Fundus photograph of a nonischemic CRVO demon
strates intraretinal hemorrhages in all 4 quadrants and dilated retinal
veins.
photocoagulation to areas of retinal ischemia for patients with a
BRVO and neovascularization.6
In ischemic BRVOs with nonclearing vitreous hemorrhage or
retinal detachment, vitreoretinal surgical techniques can remove the
hemorrhage and reattach the retina.
Central Retinal Vein Occlusion (CRVO)
Clinical Presentation
The typical patient with a CRVO is in the 60s.3 Patients describe
sudden, painless loss ofvision and occasionally, of a painful, red eye
from neovascular glaucoma secondary to an ischemic CRVO.
In an acute CRVO, ophthalmoscopy reveals intraretinal hemor
rhages in all 4 quadrants and dilated, tortuous retinal veins. (Fig 3)
The disc may be swollen, and there may be cotton-wool spots and
cystoid macular edema. Patients with an ischemic CRVO develop
anterior segment or posterior segment neovascularization which
Fig. 2.—Left eye. Venous phase fluorescein angiogram of an ischemic
superotemporal BRVO reveals leakage from the disc and retinal
neovascularization. The foveal avascular zone is enlarged and irregular.
The superotemporal macula is hypofluorescent secondary to capillary
nonperfusion.
Fig. 4.—Left eye. Recirculation phase fluorescein angiogram of a
nonischemic CRVO shows hyperfluorescent staining of the disc and retinal
veins.
manifests as new vessels on the iris, angle, disc, or retina. In
longstanding CRVOs patients can develop cystoid macular edema,
macular retinal pigment epithelium changes, and retinal venous
collaterals.
Risk factors for CRVO include cardiovascular disease, hyperten
sion, diabetes mellitus, hyperviscosity syndromes, and increased
intraocular pressure.134
Classification
Central retinal vein occlusions are categorized into ischemic and
nonischemic types. A nonischemic CRVO is defined as less than 10
disc areas of capillary nonperfusion on fluorescein angiography
while an ischemic CRVO is defined as greater than 10 disc areas of
capillary nonperfusion.89 (Fig. 4) Clinically, patients with an is
chemic CRVO have poor vision, an afferent pupillary defect, and
extensive intraretinal rr89
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Complications
Patients with a nonischemic CRVO may lose vision secondary to
macular edema. Patients with an ischemic CRVO can lose vision
from macular edema, ischemic maculopathy, neovascular glau
coma, and vitreous hemorrhage. If ischemia occurs in the macula,
a patient may notice central vision loss, while ophthalmoscopy may
not reveal macular edema. A fluorescein angiogram will demon
strate an enlarged, irregular foveal avascular zone.
A severe complication of an ischemic CRVO is anterior segment
neovascularization which occurs in about 35% of patients.8’9Un
treated anterior segment neovascularization can progress to
neovascular glaucoma and blindness. About 18% of patients with
ischemic CRVOs develop neovascularization of the retina or disc.’°
Traction from the vitreous may cause these new vessels to bleed
leading to vitreous hemorrhage and decreased vision.
Treatment
Patients with a nonischemic CRVO are followed clinically for
progression into an ischemic CRVO and its complications. About
15% of patients with a nonischemic CRVO progress to an ischemic
CRVO within 4 months.8’9The Central Vein Occlusion Study was
a multicenter, randomized, controlled clinical trial to see if argon
laser photocoagulation could improve visual acuity in eyes with a
CRVO with macular edema and vision 20/50 or worse.1’The study
found no visual acuity difference in treated and untreated eyes.
Macular grid photocoagulation is not recommended for patients that
meet the study entry criteria.”
The Central Vein Occlusion Study was also
whether panretinal argon laser photocoagula
tion could prevent anterior segment
neovascularization and neovascular glaucoma.’°
Patients with ischemic CRVOs (defined as
greater than 10 disc areas of capillary
nonperfusion as documented by fluorescein an
giography) were treated with panretinal argon
laser photocoagulation before and after devel
opment of anterior segment neovascularization.
The study proved that prophylactic laser de
creased the incidence of anterior segment
neovascularization, but laser at the time of de
velopment of anterior segment neovascu
larization prevented neovascular glaucoma. The
study investigators recommend careful follow
up of patients with an ischemic CRVO and
panretinal photocoagulation when the patient
develops two clock hours of iris neovascu
larization or any angle neovascularization.’°’ 2
Summary
Retinal vein occlusions are a common cause
of vision loss in people over age 60. Careful,
serial ophthalmoscopy aids in the initial diagno
sis and recognition of subsequent complica
tions. Laser photocoagulation is used to treat
macular edema and retinal neovascularization
secondary to a BRVO. Laser photocoagulation
is also used to prevent neovascular glaucoma in
an ischemic CRVO. Occasionally, vitreoretinal
surgical techniques are needed to remove chronic vitreous hemor
rhage or repair a retinal detachment secondary to a retinal vein
occlusion.
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WANTED
32 Athletes in peak condition to win the America’s Cup.
Requirements:
• Extraodinary cardiovascular capacity & warp-speed reflexes
• Able to climb 100-foot mast suspended from metal wire
• Must hoist 150 lbs. of sail 100 ft. in under 8 sec.
• Able to spin loaded winches at 120 rpm for up to two hours
• Able to withstand extremely cold/wet conditions
• Must work 14-hour days, 7 days/wk.
• Three year mm. committrnent req.
What does it take to bring the America’s Cup to Hawaii? Join the Aloha Racing team
and find out. Aloha Racing corporate sponsor HEALTHSOUTH Corp., the nations
largest rehabilitation provider and undisputed leader in sports medicine, has joined
our Hawaii America’s Cup Team. As members of the Hawaii healthcare industry you
too can benefit during the next three years from an association with one of the most
exciting and physically demanding sports in the world
... the America’s Cup.
If you’d like to find out how you can race with the team aboard the Aloha Racing
yacht during the next America’s Cup in Aukiand, New Zealand; how your healthcare
business can capitalize on the international marketing opportunities of this ‘healthy
challenge’ or how you can personally support the effort to bring the America’s Cup to
Hawaü, contact D. I. Cathcart with Aloha Racing at (808) 3660259.
A
WAIKIKI YACHT CLUB
AMERICA’S CUP CHALLENGE
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